Ascelia Pharma
Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
The board of directors of Ascelia Pharma AB (“Ascelia”) has on 9 November 2023 resolved to convert 34,984 series C shares into ordinary shares for delivery of shares to participants in the long-term incentive program in the form of a performance-based share saving program that was adopted at the annual general meeting held on 6 May 2020 (“LTI 2020”).
The board of directors of Ascelia has, in accordance with the provisions of LTI 2020, resolved to convert 34,984 series C shares for allotment of 34,984 ordinary shares to the participants in LTI 2020, where 11,000 ordinary shares were allotted to the CEO of Ascelia and 23,984 ordinary shares were allotted to other participants. In total, 8 participants have been allotted ordinary shares in LTI 2020.
The number of outstanding shares in Ascelia, after the registration of the above-mentioned conversion of series C shares into ordinary shares, amounts to a total of 34,871,177 shares, of which 33,757,746 are ordinary shares with one vote each and 1,113,431 are series C shares with 1/10 vote each. All series C shares are held by Ascelia. The total number of votes in Ascelia amounts to 33,869,089.1.
Datum | 2023-11-09, kl 13:52 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)